awmsg logo



lisdexamfetamine dimesylate (Elvanse®)


Reference No. 188

Publication date:
03/12/2013


Last review date:
01/12/2016

Appraisal information

lisdexamfetamine dimesylate (Elvanse®) 30 mg capsule
lisdexamfetamine dimesylate (Elvanse®) 50 mg capsule
lisdexamfetamine dimesylate (Elvanse®) 70 mg capsule


Company: Shire Pharmaceuticals Ltd
BNF category: Central nervous system
NMG meeting date: 11/09/2013
AWMSG meeting date: 16/10/2013
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2813
Ministerial ratification: 02/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Lisdexamfetamine dimesylate (Elvanse®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged six years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision of a specialist in childhood and/or adolescent behavioural disorders.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download